AB0412 Exploratory Results from The Bliss and Illuminate Trials Support The Design of The CHABLIS-SC1 Trial, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus: Table 1.